

1 **Title: An assessment of a rapid SARS-CoV-2 antigen test in Bangladesh**

2 *Zannat Kawser¹, Mohabbat Hossain¹ Sara Suliman², Shahin Lockman^{3,4}, Jesse Gitaka^{5,6}, Gama*
3 *Bandawe⁷, Redwan Rahmat¹, Imrul Hasan¹, Abu Bakar Siddik¹, Mokibul Hassan Afrad⁸,*
4 *Mohammed Ziaur Rahman⁸, Glenn Miller⁹, David R. Walt^{9,10,11}, Louise C. Ivers^{12,13}, Regina C.*
5 *LaRocque¹³, Jason B. Harris¹³, Firdausi Qadri,^{8*}*

6 **Email Adress:**

7 Zannat Kawser- zannatkawser@gmail.com
8 Mohabbat Hossain- mohabbat@ideshi.org
9 Sara Suliman- ssuliman1@bwh.harvard.edu
10 Shahin Lockman- shahin.lockman@gmail.com
11 Jesse Gitaka- jgitaka@mku.ac.ke
12 Gama Bandawe- gbandawe@must.ac.mw
13 Redwan Rahmat- redwan@ideshi.org
14 Mokibul Hassan Afrad- hassan.afrad@icddr.org
15 Mohammed Ziaur Rahman –mzrahman@icddr.org
16 Imrul Hasan- imrul@ideshi.org
17 Abu Bakar Siddik- absiddik@ideshi.org
18 Glenn Miller- GAMILLER@partners.org
19 David R. Walt- dwalt@bwh.harvard.edu

20 Louise C. Ivers- LIVERS@mgh.harvard.edu

21 Regina C. LaRocque- RCLAROCQUE@mgh.harvard.edu

22 Jason B. Harris- JBHARRIS@mgh.harvard.edu

23 Firdausi Qadri- fqadri@icddr.org

24 **Author Affiliation:**

25 ¹ institute for developing Science and Health initiatives (ideSHi), Dhaka, Bangladesh

26 ² Infectious Disease Immunologist, Division of Experimental Medicine, Zuckerberg San

27 Francisco General Hospital, USA

28 ³ Division of Infectious Diseases, Brigham and Women's Hospital, Boston MA, USA

29 ⁴ Harvard T.H. Chan School of Public Health, Boston MA, USA

30 ⁵ Directorate of Research and Innovation, Mount Kenya University, Thika, Kenya

31 ⁶ Centre for Malaria Elimination, Mount Kenya University, Thika, Kenya

32 ⁷ Biological Sciences Department, Academy of Medical Sciences, Malawi University of Science

33 and Technology, Thyolo, Malawi

34 ⁸ International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh

35 ⁹ Mass General Brigham Center for COVID Innovation, Boston, MA

36 ¹⁰ Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA

37 ¹¹ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston,

38 MA

39 ¹² Department of Global Health and Social Medicine, Harvard Medical School, Boston MA,

40 USA

41 ¹³ MGH Center for Global Health, Massachusetts General Hospital, Boston MA, USA

42

43 ***Corresponding Author:**

44 Firdausi Qadri

45 Infectious Diseases Division (IDD), icddr,b, 68, Shaheed Tajuddin Ahmed Sarani, Mohakhali,

46 Dhaka 1212, Bangladesh

47 institute for developing Science and Health initiatives (ideSHi), 9 Mohakhali C/A, Dhaka 1212,

48 Bangladesh

49 Phone: 01711595367

50 email: fqadri@icddr.org

51

52

53 Word count: 4195

54

55 Running head: Rapid SARS-CoV-2 antigen testing in Bangladesh

56

57

58 **Abstract (# 249)**

59 Early detection of SARS-CoV-2 infection is crucial to prevent the spread of the virus. In this study,
60 we evaluated the performance of a commercial rapid antigen detection test, BD Veritor, and
61 compared this (and another rapid test, Standard Q) against a gold-standard of nasopharyngeal (NP)
62 swab tested by reverse transcription-polymerase chain reaction (RT-PCR) in prospectively-
63 recruited adults in Dhaka, Bangladesh. We compared the sensitivity and specificity of the two
64 rapid antigen tests against RT-PCR results in 130 symptomatic and 130 asymptomatic adults. In
65 addition, we evaluated the suitability and ease-of-use of the BD Veritor test in a subsample of
66 study participants (n=42) and implementers (n=5). The sensitivity of the BD Veritor rapid antigen
67 test was 70% in symptomatic (95% confidence interval [CI]: 51-85%) and 87% (95% CI: 69-96%)
68 in asymptomatic individuals with positive SARSCoV-2 RT-PCR, for overall sensitivity of 78%
69 (95% CI: 66-88%). The sensitivity of the Standard Q rapid antigen test was 63% (95% CI: 44-
70 80%) in symptomatic and 73% (95% CI: 54-87%) in asymptomatic individuals. One false positive
71 in BD Veritor test (specificity 99.5) and no false positive in Standard Q tests were observed
72 (specificity 100%). The BD Veritor rapid antigen test was 78% sensitive when compared with
73 RT-PCR irrespective of the cycle threshold (Ct) levels in this evaluation in Bangladesh. The
74 implementation evaluation data showed good acceptability in the field settings. This warrants large
75 field evaluation as well as use of the rapid antigen test for quick assessment of SARS-CoV-2 for
76 containment of epidemics in the country.

77 **Key Words:** SARS-CoV-2, COVID-19, Rapid Antigen Test, RT-PCR, Implementation

78

79 **Introduction:**

80 Rapid antigen detection tests are point-of-care immunochromatographic assays which
81 detect protein antigens specific to the Severe Acute Respiratory Syndrome of the Coronavirus-2
82 (SARS-CoV-2) (e.g. nucleocapsid) (1). The ease-of-use and quick turnaround time of such tests
83 can expand access to testing and decrease delays in diagnosis (2). Furthermore, modeling studies
84 on SARS-CoV-2 have demonstrated that even if rapid antigen testing is associated with decreased
85 sensitivity, the accessibility and short turnaround time in reporting results may be advantageous
86 for decreasing transmission (3). Rapid antigen testing is particularly useful if deployed in the
87 context of repeated testing over time (4) (5).

88 The performance of the rapid antigen tests has been determined by comparing their
89 sensitivity and specificity with nucleic acid detection-based reference reaction (6). The current
90 gold standard for identifying the presence of SARS-CoV-2 is reverse transcription-polymerase
91 chain reaction (RT-PCR) in samples collected by nasopharyngeal (NP) swab (7). Despite their
92 high sensitivity, nucleic acid amplification tests are associated with the need for laboratory
93 processing, high costs, and a longer turnaround from sampling to return of results (8) (9). The NP
94 swabs are also more challenging and uncomfortable (for patients) to collect than anterior nares
95 swabs. For this reason, rapid antigen testing is a valuable tool for contact tracing and early
96 detection of COVID-19 patients to triage for treatment options, especially in settings where RT-
97 PCR is less available or where follow-up reporting of RT-PCR results is more difficult, and
98 particularly when anterior nares samples can be used.

99 In this study among asymptomatic and symptomatic adults, we evaluated the performance
100 (sensitivity/specificity) of two rapid antigen detection tests, the BD Veritor™ (Becton-Dickenson,
101 USA) and the Standard Q™ (SD-Biosensor, Korea) rapid antigen test, in comparison to NP swab
102 RT-PCR as the reference standard. The BD Veritor was performed according to the manufacturer's

103 recommendations using an anterior nares swab specimen, while the Standard Q and reference RT-
104 PCR were performed on nasopharyngeal swab specimens. We also evaluated the performance of
105 the rapid antigen tests across the spectrum of RT-PCR cycle threshold (Ct) values. Finally, we
106 assessed the implementation characteristics of the BD Veritor rapid antigen test, including fitness-
107 for-use in different populations and settings in Bangladesh.

108

109 **Methodology:**

110 *Study design and participants:* We enrolled study participants at a triage and sample collection
111 booth at Kurmitola General Hospital (n=49) as well as at the ideSHi COVID-19 testing facility
112 (n=211) in Dhaka, Bangladesh. Adults aged 18 and above were eligible for inclusion. For this
113 analysis, we aimed to enroll 130 symptomatic patients with Covid-19 like symptoms including
114 fever, cough, headache, sore throat, shortness of breath and fatigue (10) who had their onset of
115 first symptom within five days, including 100 individuals with negative RT-PCR results and 30
116 individuals with positive RT-PCR results. In addition, we aimed for a similar target for positive
117 and negative asymptomatic individuals who presented for routine COVID-19 screening at the
118 above sites (primarily occupational screening or for known contact with an individual who tested
119 positive). Written informed consent was obtained from participants. The study was approved by
120 the Research Review Committee (RRC) and Ethical Review Committee (ERC) of icddr,b
121 (Protocol no: PR- 20042).

122 *Specimen collection:* Nasopharyngeal swab specimens were collected by trained personnel and
123 placed in a 3-mL tube of viral transport medium (Citoswab, Citotest Labware Manufacturing Co.
124 Ltd, China) to be used for both Standard Q antigen testing and RT-PCR testing. Anterior nares

125 swab samples were also collected by trained personnel according to the manufacturers'
126 instructions for BD Veritor. Specifically, the swab provided with the kit was inserted into the
127 anterior nasal cavity up to 2.5 cm and rolled 5 times along the mucosal surface in both nostrils.
128 The nasopharyngeal and anterior nares swab specimens were collected simultaneously until the
129 first 200 individuals with negative RT-PCR results were enrolled in each group (100 symptomatic
130 and 100 asymptomatic). Thereafter, the anterior nares samples were collected within 24 hours of
131 the nasopharyngeal specimen until 60 individuals with positive RT-PCR results were accrued (30
132 symptomatic and 30 asymptomatic).

133 ***RT-PCR on nasopharyngeal swab specimens:*** Viral RNA was extracted from 200 μ l of viral
134 transport media using the magnetic bead based Nexor 32 Fully Automated Nucleic Acid
135 Extractor (Nucleic Acid Extraction or Purification Kit, Beijing Lepu Medical Technology Co.,
136 Ltd, China). RT-PCR was carried out using the China CDC primer and probes. In brief, this was
137 performed in a 20 μ l reaction volume and each reaction contained extracted RNA, 2x iTaq
138 Universal Probes Reaction Master Mix (Biorad, CA, USA), iScript Reverse Transcriptase,
139 the CDC_ORF1ab and N forward and reverse primers, and probe (11)(12). Specimens were
140 determined to be positive for SARS-CoV-2 when the ORF1ab and N genes were detected with an
141 exponential growth curve and a cycle threshold (Ct) value <40, and negative when these genes
142 could not be detected. The test was considered positive even if one gene was detected. The quality
143 of the nasopharyngeal specimen extracted was determined by analyzing the curve generated with
144 the *rnaseP* housekeeping gene.

145 ***Rapid Antigen Testing:*** The rapid tests were performed in accordance with the manufacturer's
146 instructions. For the BD Veritor assay, the anterior nares swab was inserted into the extraction
147 reagent tube and mixed in the fluid for a minimum of 15 seconds before discarding. Three drops

148 of the processed specimen were added to the sample well of the device, and incubated for 15
149 minutes. Following this, the test device was inserted into the Veritor Plus Analyzer (BD) for
150 reading.

151 For the Standard Q kit, 350 μ L of freshly obtained NP swab specimen in viral transport
152 medium was reconstituted in the extraction buffer supplied by the manufacturer and incubated for
153 45-50 minutes. For testing, 3 drops (approximately 80 μ L) of extracted nasopharyngeal specimen
154 was applied to the sample well of device, and results were interpreted after 15 minutes, based on
155 the manufacturer's instructions.

156 ***Assessment of implementation characteristics:*** We surveyed 5 test implementers and 42
157 participants about the BD Veritor test with a user acceptability and adoption assessment form for
158 implementers and a feedback form for participants. Five point Likert scale was used for
159 documenting the level of satisfaction and level of difficulties in addition to the qualitative aspects
160 in the questionnaire. We also assessed the BD Veritor test in comparison to NP swab RT-PCR
161 regarding resources to collect and transport samples, and use of Personal Protective Equipment
162 (PPE) and consumables. We evaluated turnaround times (from the sample collection time until the
163 result was reported to the participant) for each sample type, assay, and platform from the time of
164 collection to delivery of results.

165 ***Statistical analysis:*** We calculated the sensitivity and specificity (13) of each rapid test compared
166 with the NP RT-PCR gold standard, and reported these as a percentage with 95% confidence
167 intervals (CIs). The sensitivity of both rapid tests (combined) was also analyzed in RT-PCR
168 positive samples stratified by Ct value >30 , $20-30$, and <20 . The sensitivity of the two rapid tests
169 was compared and P value was calculated using McNemar's Chi-Square Test. In addition, the

170 comparison of Ct values between symptomatic and asymptomatic individuals was performed using
171 the Mann-Whitney U test.

172

173 **Results:**

174 We enrolled 262 individuals in this study. Two study participants were subsequently
175 excluded from the analysis because of incomplete information in the case record forms, resulting
176 in a study set of 260 individuals. Forty-nine of the symptomatic individuals were enrolled at the
177 Kurmitola General Hospital, while the remaining 211 participants included in the analysis were
178 enrolled at the ideSHi testing facility. Demographic characteristics are shown in Table 1. The
179 median age of the symptomatic individuals was 35 years (range, 18 – 81 years), and 53% were
180 male. The most common symptom was fever (N=88, 68%), and the median duration (and range)
181 of symptoms were 3 days (1 to 5 days) in the symptomatic patients. The median age of the
182 asymptomatic individuals was 33 years (range, 18 – 74), and 81% were male.

183 The sensitivity and specificity of both rapid tests are reported in Table 2. The sensitivity of
184 the BD Veritor test (78%) was higher than that of the Standard Q test (68%) (P=0.041). The
185 sensitivity of both tests was higher in asymptomatic individuals than in symptomatic individuals.
186 Only one false positive BD Veritor test was identified in a screened symptomatic individual who
187 reported a four-day history of cough with no fever, myalgia or loss of smell. No false positive
188 Standard Q tests were observed.

189 We compared the performance of both rapid antigen tests stratified by the observed Ct
190 value of the nasopharyngeal RT-PCR. There was no difference in the median Ct value between
191 the symptomatic and asymptomatic individuals (Figure 1). We also observed no significant
192 difference (P=0.2 by Mann-Whitney U) in the range of Ct values between the two groups and

193 hence considered such individuals together in the analysis stratified by Ct value (Table 2). For RT-
194 PCR samples with a Ct < 20 (i.e., those with a high amount of viral genetic material), the sensitivity
195 of both rapid antigen tests was 100%. For RT-PCR samples with a Ct > 30 (i.e., those with little
196 viral genetic material), neither rapid antigen test performed well (sensitivity <10%). For RT-PCR
197 samples with Ct values in the 20-30 range, the sensitivity of the BD Veritor test was 97% (95%
198 CI: 84-100%), compared with 81% (95% CI: 64-93%) for the Standard Q.

199 We also interviewed a subgroup of participants (n=42) within 24 hours after having
200 obtained the anterior nares swab for the BD Veritor™ rapid test and asked them about the
201 suitability of the test, the ease of the sample collection process, the ease of testing, the accuracy of
202 the test and the turnaround time. Four participants were dissatisfied with the accuracy of the result
203 by the BD Veritor™, while the remainder of the participants (n=38) were satisfied. All of the 42
204 interviewees expressed satisfaction with the sample collection process, ease of testing and the 15-
205 20 minutes turnaround time. The 5 implementers surveyed, each of whom performed more than
206 50 tests, were satisfied with the kit components, the design of the device, the kit storage conditions,
207 the quality controls, the time taken for the sequence of steps, the read-out of the results and the
208 suitability for batch testing along with sequential testing. Based on their experience, testers
209 estimated more than 100 patients could be tested and results given with the BD Veritor™ kit in
210 one 8 hour period of a working day.

211

212 **Discussion:**

213 We evaluated the performance of the BD Veritor™ rapid antigen test and also compared
214 with the Standard Q™ antigen test, for detecting SARS-CoV-2 in asymptomatic and symptomatic

215 adults in a real-world, community-based study in Bangladesh between January to April 2021. We
216 compared both tests to the gold standard RT-PCR performed on a nasopharyngeal swab. We found
217 the BD Veritor test to be more sensitive (78%) than the Standard Q (68%) in our study population.

218 The sensitivity of both rapid antigen tests was highly dependent on the Ct value of the
219 specimen evaluated. Both tests were 100% sensitive among individuals with $Ct < 20$ – those with
220 high viral loads. These findings are consistent with a study in China that reported 68% sensitivity
221 and 100% specificity when a Ct value ≤ 40 was used as a cut off, as compared with 98% sensitivity
222 and 100% specificity when Ct value ≤ 30 (14).

223 Interestingly, we found that the sensitivity of both the rapid antigen tests was also high
224 among asymptomatic individuals. . According to the RT-PCR analysis, the national prevalence
225 rate of COVID-19 in Bangladesh during 26th January–15th March ranged from 2 to 8% after which
226 the rate increased to 24% and peaked by beginning of April 2021. Of note, most of the
227 asymptomatic RT-PCR positive participants were enrolled during the period in which infections
228 surged, while most of the symptomatic individuals were enrolled prior to the surge. Therefore the
229 performance of rapid antigen might vary among population groups due to different
230 epidemiological, geographical conditions and impact of the variants of concern (VOC) circulating
231 in that time period although no difference has been found until now (5)(15). In Bangladesh, it was
232 the UK variant, followed by the he South Africa variant predominating in Bangladesh at the time
233 (<https://www.gisaid.org/>).

234 The use of anterior nares specimens for the BD Veritor rapid antigen test was an added
235 advantage, and study participants found this test to be more acceptable than the nasopharyngeal
236 swab. An additional advantage of the BD Veritor testing was that it was carried out directly at the
237 study site and results were available immediately. In several instances, study participants were

238 informed to isolate themselves until RT-PCR results confirmed the infection. In addition, the
239 analyzer provided with the kit was able to detect very faint bands on the device barely visible by
240 the naked eye which reduces the chance of human bias. Inclusion of the positive and negative
241 controls with other kit components was helpful for quality assessment of the analyzer before use.

242 A limitation of our study is that we compared rapid antigen tests that required different
243 types of clinical specimens: For the BD Veritor we used anterior nares specimens for rapid test
244 and a NP sample for PCR; the Standard Q uses only one nasopharyngeal specimen, which is
245 diluted in viral transport media and used for both PCR and rapid test. If the concentration of the
246 virus differs between AN and NP swabs, that is in the two sites of the nostril, it can also affect
247 results. However, we did not see significant discrepancies between the two tests, except when
248 specimens had high RT-PCR Ct values, indicating low viral loads. In that case both BD Veritor
249 and the Standard Q failed to detect SARS-CoV-2 virus. Notably, we also found the BD Veritor
250 rapid antigen test to be more sensitive even though the anterior nares specimen for it were collected
251 later for the RT-PCR positive individuals.

252 Our study on rapid antigen tests is timely for Bangladesh which is currently experiencing
253 a second wave and high rates of COVID-19 (16). Point of care tests are urgently needed for health
254 facilities, travelers, workplaces and the general population, and our findings can help guide the
255 implementation of these tests in Bangladesh. The BD Veritor test is sensitive enough to detect
256 cases with high viral load in pre-symptomatic and early symptomatic cases as well as
257 asymptomatic persons – groups that likely contribute to a significant proportion of transmission
258 and spread of the disease (17). The patients who test positive by rapid antigen tests can readily be
259 diagnosed with a minimum turnaround time, which offers the opportunity for early interruption of
260 transmission through targeted isolation and contact tracing, as infectivity may be high with a Ct<

261 24 or so (18). Persons with negative rapid test who are suspected of having COVID can be tested
262 by RT-PCR, depending on the epidemiologic context. Our information can provide
263 implementation guidance when deciding testing strategies in different settings.

264 Many countries are now planning the expanded use of rapid antigen tests, and our results
265 will provide guidance on their implementation in real-world settings such as that performed our
266 study site in Bangladesh. Rapid antigen tests will be a critical component of COVID-19 control
267 for the foreseeable future.

268 **Acknowledgment**

269 We gratefully acknowledge the support of Mass General Brigham (MGB) Center for COVID
270 Innovation for providing the BD Veritor plus analyzer antigen detection kits and the Massachusetts
271 General Hospital (MGH) for facilitation of the work. We thank the Bill and Melinda Gates
272 Foundation for support to icddr,b investigators. icddr,b is grateful to the Governments of
273 Bangladesh, Canada, Sweden, and the United Kingdom for providing core/unrestricted
274 support. The overall support of Fondation Merieux to ideSHi is acknowledged. We would like to
275 express our gratitude to the participants for taking part and the field site staff of ideSHi for their
276 effort to accomplish the work.

277

278 **References:**

- 279 1. Chaimayo C, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree
280 M, Angkasekwinai N, Sutthent R, Puangpunngam N, Tharmviboonsri T, Pongraweevan O,
281 Chuthapisith S, Sirivatanauksorn Y, Kantakamalakul W, Horthongkham N. 2020. Rapid
282 SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for
283 laboratory diagnosis of COVID-19 in Thailand. *Virology* 17:1–7.
- 284 2. Eshghifar N, Busheri A, Shrestha R, Beqaj S. 2021. Evaluation of analytical performance
285 of seven rapid antigen detection kits for detection of SARS-CoV-2 virus. *Int J Gen Med*
286 14:435–440.
- 287 3. Kennedy-Shaffer L, Baym M, Hanage WP. 2021. Perfect as the enemy of good: tracing
288 transmissions with low-sensitivity tests to mitigate SARS-CoV-2 outbreaks. *The Lancet*
289 *Microbe* 2:e219–e224.
- 290 4. Johansson MA, Wolford H, Paul P, Diaz PS, Chen TH, Brown CM, Cetron MS, Alvarado-
291 Ramy F. 2020. Reducing travel-related SARS-CoV-2 transmission with layered mitigation
292 measures: Symptom monitoring, quarantine, and testing. *medRxiv* 1–13.
- 293 5. Holmdahl I, Kahn R, Hay JA, Buckee CO, Mina MJ. 2021. Estimation of Transmission of
294 COVID-19 in Simulated Nursing Homes With Frequent Testing and Immunity-Based
295 Staffing. *JAMA Netw Open* 4:e2110071.
- 296 6. WHO. 2020. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid
297 immunoassays Interim guidance, 11 September 2020. *World Heal Organ* 1–9.
- 298 7. Olalekan A, Iwalokun B, Akinloye OM, Popoola O, Samuel TA, Akinloye O. 2020.

- 299 COVID-19 rapid diagnostic test could contain transmission in low- And middle-income
300 countries. *Afr J Lab Med* 9:1–8.
- 301 8. Lambert-niclot S, Cuffel A, Pape L, Vauloup-fellous C, Morand-joubert L. 15635.
302 Evaluation of a Rapid Diagnostic Assay for Detection of. *J Clin Microbiol* 58:e00977-20.
- 303 9. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, Chen H,
304 Mubareka S, Gubbay JB, Chan WCW. 2020. Diagnosing COVID-19: The Disease and
305 Tools for Detection. *ACS Nano* 14:3822–3835.
- 306 10. Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. 2021. Features, evaluation, and
307 treatment of coronavirus (COVID-19). *StatPearls*.
- 308 11. Jung Y, Park GS, Moon JH, Ku K, Beak SH, Lee CS, Kim S, Park EC, Park D, Lee JH,
309 Byeon CW, Lee JJ, Maeng JS, Kim SJ, Kim S Il, Kim BT, Lee MJ, Kim HG. 2020.
310 Comparative Analysis of Primer-Probe Sets for RT-qPCR of COVID-19 Causative Virus
311 (SARS-CoV-2). *ACS Infect Dis* 6:2513–2523.
- 312 12. CDC. 2020. 2019-Novel Coronavirus (2019-nCoV) Real-time rRT-PCR Panel Primers
313 and Probes Note : Oligonucleotide sequences are subject to future changes as the 2019-
314 Novel Coronavirus. *Div Viral Dis Centers Dis Control Prev* 2.
- 315 13. Smith CJ. 2012. Diagnostic tests (1) - sensitivity and specificity. *Phlebology* 27:250–251.
- 316 14. Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han C, Chen J, Pan Y, Chen L, Dan Y, Wang J,
317 Chen Y, Deng G, Zhou H, Wu Y. 2020. Diagnosis of acute respiratory syndrome
318 coronavirus 2 infection by detection of nucleocapsid protein. *medRxiv*
319 <https://doi.org/10.1101/2020.03.07.20032524>.

- 320 15. Saeed U, Uppal SR, Piracha ZZ, Rasheed A, Aftab Z, Zaheer H, Uppal R. 2021. Evaluation
 321 of SARS-CoV-2 antigen-based rapid diagnostic kits in Pakistan: formulation of COVID-19
 322 national testing strategy. *Viol J* 18:1–5.
- 323 16. 2021. Experts: Bangladesh’s second Covid wave has peaked, situation likely to improve in
 324 May. *Dhaka Tribune*.
- 325 17. ECDC. 2020. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and
 326 the UK.
- 327 18. Street L. 2016. Predicting infectious SARS-CoV-2 from diagnostic samples 306:0–19.

328 **Tables.**

329

330 **Table 1: Demographic characteristics in different groups of participants.**

Characteristic	Symptomatic		Asymptomatic	
	PCR+(n=30)	PCR-(n=100)	PCR+(n=30)	PCR-(n=100)
Median Age	46.5	32	33.5	33
Sex				
Male	15(50%)	54(54%)	29(96%)	76(76%)
Female	15(50%)	46(46%)	1(4%)	24(24%)
Population category				
Traveler	0 (0%)	0 (0%)	19 (63.3%)	27 (27%)
Student	4 (13.3%)	19 (19%)	2 (6.7%)	1 (1%)
Healthcare worker	3 (10%)	6 (6%)	0 (0%)	2 (2%)
General population	23 (76.6%)	75 (75%)	9 (30%)	70 (70%)

**Symptom spectrum				-	-
Fever alone	1 (3.3%)	13 (13%)			
Fever+Cough	4 (13.3%)	7 (7%)			
Fever+Headache	0 (0%)	5 (5%)			
Fever+Cough+Headache	5 (16.7%)	10 (10%)			
Symptoms without fever	7 (23.3%)	35 (35%)			
History of contact	15 (50%)	43 (43%)	7 (23.3%)		3 (3%)
History of regular use of mask	27 (90%)	89 (89%)	24 (80%)		97 (97%)

331 *Health care worker; **Other symptoms not mentioned indicate sore throat, shortness of breath,
 332 diarrhea, loss of taste and/or loss of smell, generalized weakness

333 **Table 2: Performance of two rapid antigen detection tests for detection of SARS-CoV-2 in**
 334 **comparison to nasopharyngeal RT-PCR.**


Category		*BD + (n)	BD - (n)	BD performance (95% CI)	*Standard Q + (n)	Standard Q - (n)	Standard Q performance (95% CI)
Symptomatic	PCR + (N=30)	21	9	Sensitivity 70% (54-88%)	19	11	Sensitivity 63% (47-83%)
	PCR - (N=100)	1	99	Specificity 99% (95-100%)	0	100	Specificity 100% (69-100%)
Asymptomatic	PCR + (N=30)	26	4	Sensitivity 87% (69-96%)	22	8	Sensitivity 73% (61-92%)
	PCR - (N=100)	0	100	Specificity 100% (69-100%)	0	100	Specificity 100% (69-100%)
Overall sensitivity and specificity (both symptomatic and asymptomatic participants)							
Positive PCR	N = 60	47	13	Sensitivity 78% (66-88%)	41	19	Sensitivity 68% (55-80%)
Negative PCR	N= (200)	1	199	Specificity 99.5% (97-100%)	0	200	Specificity 100% (98-100%)
Combined symptomatic and asymptomatic categorized by RT-PCR cycle threshold (Ct) value							

Ct > 30	N = 13	1	12	Sensitivity 8% (0-36%)	0	13	Sensitivity 0% (0-25%)
Ct 20-30	N = 32	31	1	Sensitivity 97% (84-100%)	26	6	Sensitivity 81% (64-93%)
Ct < 20	N = 15	15	0	Sensitivity 100% (78-100%)	15	0	Sensitivity 100% (78-100%)

335 *For BD Veritor™ testing kit, anterior nares specimens and for Standard Q, nasopharyngeal

336 specimen were tested based on manufacturer's instruction.

337 **Figures.**



338

339 **Figure 1. Comparison of Ct values among symptomatic and asymptomatic study**

340 **participants, and across rapid antigen tests.** The was no significant difference in the median

341 Ct value in PCR positive symptomatic and asymptomatic participants, however, the median Ct

342 values were significantly higher in individuals with false negative rapid antigen tests.